Latest News in Biostatistics
New research led by three Yale School of Medicine scientists aims to achieve better understanding of the molecular effects of alcohol use disorder (AUD) on certain regions of the brain.
- July 03, 2024
Yale School of Public Health researchers evaluate the association between exposure to hot temperatures during pregnancy and the risk of cancer in children.
- July 02, 2024
The Journal of the American College of Cardiology (JACC), one of the leading cardiovascular journals worldwide, recently named several Yale faculty members to its editorial board.
- June 25, 2024Source: NIH Fogarty: Global Health Matters May/June 2024
Dr. Denise Esserman, Professor of Biostatistics and Co-Director of the Yale Center for Analytical Sciences Leads Georgian Implementation Science Fogarty Training Program.
- June 25, 2024
McCall designs digital health tools that have the potential to reduce health inequities by facilitating connections to health and social services.
- June 05, 2024
The Yale School of Public Health (YSPH) has announced the appointment of two new assistant professors, Lee Kennedy-Shaffer, PhD, and Qiao Liu, PhD, in the Department of Biostatistics.
- June 04, 2024
Negative early life experiences, such as attending segregated schools, contribute significantly to cognitive decline and cognition disparities between older Black and white Americans, according to a new study led by researchers at the Yale School of Public Health.
- May 29, 2024Source: Yale News
Yale School of Public Health researchers assessed how long international travelers should be quarantined to prevent COVID-19 infection rise, finding it differed quite a bit by country.
- May 23, 2024
Yale School of Public Health Associate Dean of Research Melinda Irwin announces the recipients of this year’s top research awards.
- May 22, 2024
In a new research letter in JAMA, Mona Sharifi, MD, MPH, and a team of researchers looked at the dispensing of glucagon-like peptide-1 receptor agonists (GLP-1RA) medications to adolescents and young adults (AYAs), aged 12-17 years. GLP-1RA medications have been approved for use in adults with Type 2 diabetes and for adults with obesity for many years, but national attention increased around the FDA approval of semaglutide for weight loss in 2021 for adults and December 2022 for adolescents with obesity.